Inclusion Criteria:

- Biopsy proven, metastatic nasopharyngeal carcinoma (NPC) (WHO grade III) and
measurable metastatic disease.

- ECOG performance status <2.

- Life expectancy greater than 6 months.

- Patient must have adequate access for leukapheresis (vein or central line)

- Patients must have normal organ and marrow function as defined below:

1. leukocytes >3,500/μl, absolute neutrophil count >1,500/μl, platelets
>100,000/μl.

2. Organ function tests:

3. total bilirubin <1.5X normal, AST(SGOT) / ALT(SGPT) <2.5 X of normal or <5X in
the case of patients with liver metastases;

4. creatinine <1.5X normal institutional limits or a calculated creatinine
clearance of > 50 mls/min.

- Negative pregnancy test within 4 weeks of enrollment in women of child-bearing age.

- Patients with fertility/child bearing potential must agree to avoid pregnancy.

- Age 18 and older

- Patients must have received at least one prior systemic treatments for "metastatic
nasopharyngeal carcinoma".Neoadjuvant chemotherapy or concurrent chemoradiation
administered for localized disease does is not considered a line of prior treatment.

- Patient's last dose of systemic chemotherapy must have been given at least 4 weeks
prior to the beginning of study treatment. Local radiation therapy will be allowed
only if there are other sites of measurable disease.

- Patients must have at least one site of measurable disease. Sites of measurable
disease which has been irradiated can be used if greater than 60 days has passed
between the completion of radiation treatment and the start of NK cell treatment.

Exclusion Criteria:

- Patients with active infections requiring oral or intravenous antibiotics are not
eligible for entry onto the study until resolution of the infection.

- History of HIV infection, chronic active Hepatitis B or C.

- Patients with prior or currently active autoimmune disease requiring management with
systemic immunosuppression are not eligible. Asthma or chronic obstructive pulmonary
disease that does not require daily systemic corticosteroids is acceptable.

- Enrollment on another experimental treatment within 28 days of starting treatment on
this study.

- Systemic steroids within 28 days of starting study treatment.

- Uncontrolled medical problems.